HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
CABOMETYX safely and effectively. See full prescribing information
for CABOMETYX.

• 

CABOMETYX™ (cabozantinib) tablets, for oral use
Initial U.S. Approval: 2012

• 

__________________ INDICATIONS AND USAGE _________________
CABOMETYX is a kinase inhibitor indicated for the treatment of patients
with advanced renal cell carcinoma (RCC) who have received prior anti­
angiogenic therapy.

• 
• 

_______________DOSAGE AND ADMINISTRATION ______________

• 
• 
• 

___________________ ADVERSE REACTIONS ___________________
The most commonly reported (≥ 25%) adverse reactions are: diarrhea, fatigue,
nausea, decreased appetite, palmar-plantar erythrodysesthesia syndrome
(PPES), hypertension, vomiting, weight decreased, and constipation. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Exelixis, Inc.
at 1-855-500-3935 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Recommended Dose: 60 mg orally, once daily. (2.1)
Instruct patients not to eat for at least 2 hours before and at least 1
hour after taking CABOMETYX. (2.1)
Do NOT substitute CABOMETYX tablets with cabozantinib
capsules. (2.1)

______________ DOSAGE FORMS AND STRENGTHS _____________
20 mg, 40 mg, and 60 mg tablets. (3)

___________________ DRUG INTERACTIONS____________________
• 
Strong CYP3A4 inhibitors: Reduce the CABOMETYX dosage.
(2.2, 7)
• 
Strong CYP3A4 inducers: Increase the CABOMETYX dosage.
(2.2, 7)

___________________ CONTRAINDICATIONS ___________________
None. (4)
_______________ WARNINGS AND PRECAUTIONS_______________

• 
• 
• 
• 

______________ USE IN SPECIFIC POPULATIONS _______________
• 
Mild to Moderate Hepatic Impairment: Reduce the CABOMETYX
dosage. (2.2, 8.6)
• 
Lactation: Advise not to breastfeed while taking CABOMETYX.
(8.2)

Hemorrhage: Do not administer CABOMETYX if recent history of
severe hemorrhage. (5.1)
GI Perforations and Fistulas: Monitor for symptoms. Discontinue
CABOMETYX for fistulas that cannot be adequately managed or
perforations. (5.2)
Thrombotic Events: Discontinue CABOMETYX for myocardial
infarction, cerebral infarction, or other serious arterial
thromboembolic events. (5.3)
Hypertension and Hypertensive Crisis: Monitor blood pressure
regularly. Discontinue CABOMETYX for hypertensive crisis or

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling.
Revised: 04/2016

FULL PRESCRIBING INFORMATION: CONTENTS*
1
2

3
4
5

6
7
8

INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATION
2.1 Recommended Dose
2.2 Dosage Adjustments
DOSAGE FORMS AND STRENGTHS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
5.1 Hemorrhage
5.2 GI Perforations and Fistulas
5.3 Thrombotic Events
5.4 Hypertension and Hypertensive Crisis
5.5 Diarrhea
5.6 Palmar-Plantar Erythrodysesthesia Syndrome
5.7 Reversible Posterior Leukoencephalopathy Syndrome
5.8 Embryo-fetal Toxicity
ADVERSE REACTIONS
6.1 Clinical Trial Experience
DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONS

10
11
12

13
14
16
17

8.1 Pregnancy
8.2 Lactation
8.3 Females and Males of Reproductive Potential
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Hepatic Impairment
8.7 Renal Impairment
OVERDOSAGE
DESCRIPTION
CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
CLINICAL STUDIES
HOW SUPPLIED/STORAGE AND HANDLING
PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information
are not listed.

1
Reference ID: 3924269

severe hypertension that cannot be controlled with anti­
hypertensive therapy. (5.4)
Diarrhea: May be severe. Interrupt CABOMETYX treatment
immediately until diarrhea resolves or decreases to Grade 1.
Recommend standard antidiarrheal treatments. (5.5)
Palmar-plantar erythrodysesthesia syndrome (PPES): Interrupt
CABOMETYX treatment until PPES resolves or decreases to
Grade 1. (5.6)
Reversible posterior leukoencephalopathy syndrome (RPLS):
Discontinue CABOMETYX. (5.7)
Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of
reproductive potential of the potential risk to a fetus and to use
effective contraception. (5.8, 8.1, 8.3)

 FULL PRESCRIBING INFORMATION

1

INDICATIONS AND USAGE

CABOMETYX is indicated for the treatment of patients with advanced renal cell carcinoma
(RCC) who have received prior anti-angiogenic therapy.

2

DOSAGE AND ADMINISTRATION

2.1

Recommended Dose

Do not substitute CABOMETYX tablets with cabozantinib capsules.
The recommended daily dose of CABOMETYX is 60 mg. Do not administer CABOMETYX
with food. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking
CABOMETYX. Continue treatment until patient no longer experiences clinical benefit or
experiences unacceptable toxicity.
Swallow CABOMETYX tablets whole. Do not crush CABOMETYX tablets.
Do not take a missed dose within 12 hours of the next dose.
Do not ingest foods (e.g., grapefruit, grapefruit juice) or nutritional supplements that are known
to inhibit cytochrome P450 during CABOMETYX treatment.

2.2

Dosage Adjustments

For Patients Undergoing Surgery
Stop treatment with CABOMETYX at least 28 days prior to scheduled surgery, including dental
surgery.
For Adverse Reactions
Withhold CABOMETYX for NCI CTCAE Grade 4 adverse reactions, and for Grade 3 or
intolerable Grade 2 adverse reactions that cannot be managed with a dose reduction or supportive
care.
Upon resolution/improvement (i.e., return to baseline or resolution to Grade 1) of an adverse
reaction, reduce the dose as follows:
•  If previously receiving 60 mg daily dose, resume treatment at 40 mg daily
•  If previously receiving 40 mg daily dose, resume treatment at 20 mg daily
•  If previously receiving 20 mg daily dose, resume at 20 mg if tolerated, otherwise, discontinue
CABOMETYX
Permanently discontinue CABOMETYX for any of the following:
•  development of unmanageable fistula or GI perforation
•  severe hemorrhage
2

Reference ID: 3924269

 •

arterial thromboembolic event (e.g., myocardial infarction, cerebral infarction)

•

hypertensive crisis or severe hypertension despite optimal medical management

•

nephrotic syndrome

•

reversible posterior leukoencephalopathy syndrome

In Patients Concurrently Taking a Strong CYP3A4 Inhibitor
Reduce the daily CABOMETYX dose by 20 mg (for example, from 60 mg to 40 mg daily or
from 40 mg to 20 mg daily). Resume the dose that was used prior to initiating the CYP3A4
inhibitor 2 to 3 days after discontinuation of the strong inhibitor [see Drug Interactions (7),
Clinical Pharmacology (12.3)].
In Patients Concurrently Taking a Strong CYP3A4 Inducer
Increase the daily CABOMETYX dose by 20 mg (for example, from 60 mg to 80 mg daily or
from 40 mg to 60 mg daily) as tolerated. Resume the dose that was used prior to initiating the
CYP3A4 inducer 2 to 3 days after discontinuation of the strong inducer. The daily dose of
CABOMETYX should not exceed 80 mg [see Drug Interactions (7), Clinical Pharmacology
(12.3)].
In Patients with Hepatic Impairment
Reduce the starting dose of CABOMETYX to 40 mg once daily in patients with mild or
moderate hepatic impairment. CABOMETYX is not recommended for use in patients with
severe hepatic impairment [see Use in Specific Populations (8.6), Clinical Pharmacology
(12.3)].

3

DOSAGE FORMS AND STRENGTHS

60 mg CABOMETYX tablets are yellow film-coated, oval shaped with no score, and debossed
with “XL” on one side and “60” on the other side.
40 mg CABOMETYX tablets are yellow film-coated, triangle shaped with no score, and
debossed with “XL” on one side and “40” on the other side.
20 mg CABOMETYX tablets are yellow film-coated, round with no score, and debossed with
“XL” on one side and “20” on the other side.

4

CONTRAINDICATIONS

None.

3

Reference ID: 3924269

 5

WARNINGS AND PRECAUTIONS

5.1

Hemorrhage

Severe hemorrhage occurred with CABOMETYX. The incidence of Grade ≥ 3 hemorrhagic
events was 2.1% in CABOMETYX-treated patients and 1.6% in everolimus-treated patients.
Fatal hemorrhages also occurred in the cabozantinib clinical program.
Do not administer CABOMETYX to patients that have or are at risk for severe hemorrhage.

5.2

GI Perforations and Fistulas

In a randomized study in renal cell carcinoma, fistulas were reported in 1.2% (including 0.6%
anal fistula) of CABOMETYX-treated patients and 0% of everolimus-treated patients.
Gastrointestinal (GI) perforations were reported in 0.9% of CABOMETYX-treated patients and
0.6% of everolimus-treated patients. Fatal perforations occurred in the cabozantinib clinical
program.
Monitor patients for symptoms of fistulas and perforations. Discontinue CABOMETYX in
patients who experience a fistula which cannot be appropriately managed or a GI perforation.

5.3

Thrombotic Events

CABOMETYX treatment results in an increased incidence of thrombotic events. Venous
thromboembolism was reported in 7.3% of CABOMETYX-treated patients and 2.5% of
everolimus-treated patients. Pulmonary embolism occurred in 3.9% of CABOMETYX-treated
patients and 0.3% of everolimus-treated patients. Events of arterial thromboembolism were
reported in 0.9% of CABOMETYX-treated patients and 0.3% of everolimus-treated patients.
Fatal thrombotic events occurred in the cabozantinib clinical program.
Discontinue CABOMETYX in patients who develop an acute myocardial infarction or any other
arterial thromboembolic complication.

5.4

Hypertension and Hypertensive Crisis

CABOMETYX treatment results in an increased incidence of treatment-emergent hypertension.
Hypertension was reported in 37% (15% Grade ≥ 3) of CABOMETYX-treated patients and 7.1%
(3.1% Grade ≥ 3) of everolimus-treated patients. Monitor blood pressure prior to initiation and
regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not
adequately controlled with medical management; when controlled, resume CABOMETYX at a
reduced dose. Discontinue CABOMETYX for severe hypertension that cannot be controlled with
anti-hypertensive therapy. Discontinue CABOMETYX if there is evidence of hypertensive crisis
or severe hypertension despite optimal medical management.

5.5

Diarrhea

Diarrhea occurred in 74% of patients treated with CABOMETYX and in 28% of patients treated
with everolimus. Grade 3 diarrhea occurred in 11% of CABOMETYX-treated patients and in
2% of everolimus-treated patients. Withhold CABOMETYX in patients who develop intolerable
Grade 2 diarrhea or Grade 3-4 diarrhea that cannot be managed with standard antidiarrheal
4

Reference ID: 3924269

 treatments until improvement to Grade 1; resume CABOMETYX at a reduced dose. Dose
modification due to diarrhea occurred in 26% of patients.

5.6

Palmar-Plantar Erythrodysesthesia Syndrome

Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 42% of patients treated with
CABOMETYX and in 6% of patients treated with everolimus. Grade 3 PPES occurred in 8.2%
of CABOMETYX-treated patients and in <1% of everolimus-treated patients. Withhold
CABOMETYX in patients who develop intolerable Grade 2 PPES or Grade 3 PPES until
improvement to Grade 1; resume CABOMETYX at a reduced dose. Dose modification due to
PPES occurred in 16% of patients.

5.7

Reversible Posterior Leukoencephalopathy Syndrome

Reversible Posterior Leukoencephalopathy Syndrome (RPLS), a syndrome of subcortical
vasogenic edema diagnosed by characteristic finding on MRI, occurred in the cabozantinib
clinical program. Perform an evaluation for RPLS in any patient presenting with seizures,
headache, visual disturbances, confusion or altered mental function. Discontinue CABOMETYX
in patients who develop RPLS.

5.8

Embryo-fetal Toxicity

Based on data from animal studies and its mechanism of action, CABOMETYX can cause fetal
harm when administered to a pregnant woman. Cabozantinib administration to pregnant animals
during organogenesis resulted in embryolethality at exposures below those occurring clinically at
the recommended dose, and in increased incidences of skeletal variations in rats and visceral
variations and malformations in rabbits. Advise pregnant women of the potential risk to a fetus.
Advise females of reproductive potential to use effective contraception during treatment with
CABOMETYX and for 4 months after the last dose [See Use in Specific Populations (8.1), (8.3),
and Clinical Pharmacology (12.1)].

6

ADVERSE REACTIONS

The following serious adverse reactions are discussed elsewhere in the label:
• 
• 
• 
• 
• 
• 
• 

Hemorrhage [see Warnings and Precautions (5.1)]
GI Perforations and Fistulas [see Warnings and Precautions (5.2)]
Thrombotic Events [see Warnings and Precautions (5.3)]
Hypertension and Hypertensive Crisis [see Warnings and Precautions (5.4)]
Diarrhea [see Warnings and Precautions (5.5)]
Palmar-plantar erythrodysesthesia syndrome [see Warnings and Precautions (5.6)]
Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions
(5.7)]

5

Reference ID: 3924269

 6.1

Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates
observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials
of another drug and may not reflect the rates observed in practice.
The safety of CABOMETYX was evaluated in Study 1, a randomized, open-label trial in which
331 patients with advanced renal cell carcinoma received 60 mg CABOMETYX and 322
patients received 10 mg everolimus administered daily until disease progression or unacceptable
toxicity. Patients on both arms who had disease progression could continue treatment at the
discretion of the investigator [see Clinical Studies (14)]. The median duration of treatment was
7.6 months (range 0.3 – 20.5) for patients receiving CABOMETYX and 4.4 months (range 0.21
– 18.9) for patients receiving everolimus.
Adverse reactions which occurred in ≥ 25% of CABOMETYX-treated patients included, in order
of decreasing frequency: diarrhea, fatigue, nausea, decreased appetite, palmar-plantar
erythrodysesthesia syndrome (PPES), hypertension, vomiting, weight decreased, and
constipation. Grade 3-4 adverse reactions and laboratory abnormalities which occurred in ≥ 5%
of patients were hypertension, diarrhea, fatigue, palmar-plantar erythrodysesthesia syndrome,
hyponatremia, hypophosphatemia, hypomagnesemia, lymphocytes decreased, anemia,
hypokalemia, and GGT increased.
The dose was reduced in 60% of patients receiving CABOMETYX and in 24% of patients
receiving everolimus. Twenty percent (20%) of patients received 20 mg CABOMETYX as their
lowest dose. The most frequent adverse reactions leading to dose reduction in patients treated
with CABOMETYX were: diarrhea, PPES, fatigue, and hypertension. Adverse reactions led to
study treatment being held in 70% patients receiving CABOMETYX and in 59% patients
receiving everolimus. Adverse reactions led to study treatment discontinuation in 10% of
patients receiving CABOMETYX and in 10% of patients receiving everolimus. The most
frequent adverse reactions leading to permanent discontinuation in patients treated with
CABOMETYX were decreased appetite (2%) and fatigue (1%).
Table 1.

Adverse Reactions Occurring in ≥ 10% Patients Who Received CABOMETYX
CABOMETYX
Everolimus
(n=331) 1
(n=322)
All
Grade
All
Grade
Grades2
3-4
Grades2
3-4
Percentage (%) of Patients

Adverse Reaction

Gastrointestinal Disorders
Diarrhea
Nausea
Vomiting
Stomatitis
Constipation
Abdominal pain 3
Dyspepsia
General Disorders and Administration Site
Conditions
Fatigue

6
Reference ID: 3924269

74
50
32
22
25
23
12

11
4
2
2
<1
4
<1

28
28
14
24
19
13
5

2
<1
<1
2
<1
2
0

56

9

47

7

 Mucosal inflammation
19
<1
23
3
Asthenia
19
4
16
2
Metabolism and Nutrition Disorders
Decreased appetite
46
3
34
<1
Skin and Subcutaneous Tissue Disorders
Palmar-plantar erythrodysesthesia syndrome
42
8
6
<1
Rash 4
23
<1
43
<1
Dry skin
11
0
10
0
Vascular Disorders
Hypertension 5
39
16
8
3
Investigations
Weight decreased
31
2
12
0
Nervous System Disorders
Dysgeusia
24
0
9
0
Headache
11
<1
12
<1
Dizziness
11
0
7
0
Endocrine Disorders
Hypothyroidism
21
0
<1
<1
Respiratory, Thoracic, and Mediastinal
Disorders
Dysphonia
20
<1
4
0
Dyspnea
19
3
29
4
Cough
18
<1
33
<1
Blood and Lymphatic Disorders
Anemia
17
5
38
16
Musculoskeletal and Connective Tissue Disorders
Pain in extremity
14
1
8
<1
Muscle spasms
13
0
5
0
Arthralgia
11
<1
14
1
Renal and Urinary Disorders
Proteinuria
12
2
9
<1
1
One subject randomized to everolimus received cabozantinib.
2
National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
3
Includes PT terms abdominal pain, abdominal pain upper, and abdominal pain lower
4
Includes PT terms rash, rash erythematous, rash follicular, rash macular, rash papular, rash pustular,
rash vesicular, genital rash, intermittent leg rash, rash on scrotum and penis, rash maculo-papular, rash
pruritic, contact dermatitis, dermatitis acneiform
5
Includes PT terms hypertension, blood pressure increased, hypertensive crisis, blood pressure
fluctuation

Other clinically important adverse reactions (all grades) that were reported in <10% of patients
treated with CABOMETYX included: wound complications (2%), convulsion (<1%),
pancreatitis (<1%), osteonecrosis of the jaw (<1%), and hepatitis cholestatic (<1%).

7

Reference ID: 3924269

 Table 2.

Laboratory Abnormalities Occurring in ≥ 25% Patients Who Received
CABOMETYX
CABOMETYX
(n=331)
All
Grade 3-4
Grades

Test

Everolimus
(n=322)
All
Grade 3-4
Grades

Chemistry
AST increased
74
3
40
<1
ALT increased
68
3
32
<1
Creatinine increased
58
<1
71
0
Triglycerides increased
53
4
73
13
Hypophosphatemia
48
8
36
5
Hyperglycemia
37
2
59
8
Hypoalbuminemia
36
2
28
<1
ALP increased
35
2
29
1
Hypomagnesemia
31
7
4
<1
Hyponatremia
30
8
26
6
GGT increased
27
5
43
9
Hematology
White blood cells decreased
35
<1
31
<1
Absolute neutrophil count decreased
31
2
17
<1
Hemoglobin decreased
31
4
71
17
Lymphocytes decreased
25
7
39
12
Platelets decreased
25
<1
27
<1
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT,
gamma glutamyl transferase.
National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0

7

DRUG INTERACTIONS

Table 3. Clinically Significant Drug Interactions Involving Drugs that Affect Cabozantinib
Strong CYP3A4 Inhibitors
Clinical Implications:

• Concomitant use of CABOMETYX with a strong CYP3A4
inhibitor increased the exposure of cabozantinib compared to
the use of CABOMETYX alone [see Clinical Pharmacology
(12.3)].
• Increased cabozantinib exposure may increase the risk of
exposure-related toxicity.

Prevention or Management: Reduce the dosage of CABOMETYX if concomitant use with
strong CYP3A4 inhibitors cannot be avoided [see Dosage and
Administration (2.2)].

8
Reference ID: 3924269

 Examples: Boceprevir, clarithromycin, conivaptan, grapefruit juicea,
indinavir, itraconazole, ketoconazole, lopinavir/ritonavir,
nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir,
telithromycin, and voriconazole
Strong CYP3A4 Inducers
Clinical Implications:

• Concomitant use of CABOMETYX with a strong CYP3A4
inducer decreased the exposure of cabozantinib compared to
the use of CABOMETYX alone [see Clinical Pharmacology
(12.3)].
• Decreased cabozantinib exposure may lead to reduced
efficacy.

Prevention or Management: Increase the dosage of CABOMETYX if concomitant use with
strong CYP3A4 inducers cannot be avoided [see Dosage and
Administration (2.2)].
Examples: Rifampin, phenytoin, carbamazepine, phenobarbital, rifabutin,
rifapentine, and St. John’s Wortb
a

The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation
dependent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain
preparation was used (e.g., high dose, double strength) or as a “moderate CYP3A inhibitor” when another
preparation was used (e.g., low dose, single strength).
b
The effect of St. John’s Wort varies widely and is preparation-dependent

8

USE IN SPECIFIC POPULATIONS

8.1

Pregnancy

Risk Summary
Based on findings from animal studies and its mechanism of action, CABOMETYX can cause
fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There
are no available data in pregnant women to inform the drug-associated risk. In animal
developmental and reproductive toxicology studies administration of cabozantinib to pregnant
rats and rabbits during organogenesis resulted in embryofetal lethality and structural anomalies at
exposures that were below those occurring clinically at the recommended dose [see Nonclinical
Toxicology (13.1)]. Advise pregnant women or women of childbearing potential of the potential
hazard to a fetus.
The estimated background risk of major birth defects and miscarriage for the indicated
population is unknown. In the U.S. general population, the estimated background risk of major
birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%,
respectively.

9

Reference ID: 3924269

 Data
Animal Data
In an embryo-fetal development study in pregnant rats, daily oral administration of cabozantinib
throughout organogenesis caused increased embryo-fetal lethality compared to controls at a dose
of 0.03 mg/kg (approximately 0.12-fold of human AUC at the recommended dose). Findings
included delayed ossification and skeletal variations at a dose of 0.01 mg/kg/day (approximately
0.04-fold of human AUC at the recommended dose).
In pregnant rabbits, daily oral administration of cabozantinib throughout organogenesis resulted
in findings of visceral malformations and variations including reduced spleen size and missing
lung lobe at 3 mg/kg (approximately 1.1-fold of the human AUC at the recommended dose).
In a pre- and postnatal study in rats, cabozantinib was administered orally from gestation day 10
through postnatal day 20. Cabozantinib did not produce adverse maternal toxicity or affect
pregnancy, parturition or lactation of female rats, and did not affect the survival, growth or
postnatal development of the offspring at doses up to 0.3 mg/kg/day (0.05-fold of the maximum
recommended clinical dose).

8.2

Lactation

Risk Summary
There is no information regarding the presence of cabozantinib or its metabolites in human milk,
or their effects on the breastfed infant, or milk production. Because of the potential for serious
adverse reactions in a breastfed infant from CABOMETYX, advise a lactating woman not to
breastfeed during treatment with CABOMETYX and for 4 months after the final dose.

8.3

Females and Males of Reproductive Potential

Contraception
Females
CABOMETYX can cause fetal harm when administered to a pregnant woman [see Use in
Specific Populations (8.1)]. Advise females of reproductive potential to use effective
contraception during treatment with CABOMETYX and for 4 months after the final dose.
Infertility
Females and Males
Based on findings in animals, CABOMETYX may impair fertility in females and males of
reproductive potential [see Nonclinical Toxicology (13.1)].

8.4

Pediatric Use

The safety and effectiveness of CABOMETYX in pediatric patients have not been studied.
Juvenile Animal Data
Juvenile rats were administered cabozantinib daily at doses of 1 or 2 mg/kg/day from Postnatal
Day 12 (comparable to less than 2 years in humans) through Postnatal Day 35 or 70. Mortalities
10

Reference ID: 3924269

 occurred at doses equal and greater than 1 mg/kg/day (approximately 0.16 times the clinical dose
of 60 mg/day based on body surface area). Hypoactivity was observed at both doses tested on
Postnatal Day 22. Targets were generally similar to those seen in adult animals, occurred at both
doses, and included the kidney (nephropathy, glomerulonephritis), reproductive organs,
gastrointestinal tract (cystic dilatation and hyperplasia in Brunner’s gland and inflammation of
duodenum; and epithelial hyperplasia of colon and cecum), bone marrow (hypocellularity and
lymphoid depletion), and liver. Tooth abnormalities and whitening as well as effects on bones
including reduced bone mineral content and density, physeal hypertrophy, and decreased cortical
bone also occurred at all dose levels. Recovery was not assessed at the 2 mg/kg dose level
(approximately 0.32 times the clinical dose of 60 mg based on body surface area) due to high
levels of mortality. At the low dose level, effects on bone parameters were partially resolved but
effects on the kidney and epididymis/testis persisted after treatment ceased.

8.5

Geriatric Use

In the Phase 3 study, 41% of RCC patients treated with CABOMETYX were age 65 years and
older, and 8% were age 75 and older. No differences in safety or efficacy were observed between
older and younger patients.

8.6

Hepatic Impairment

Increased exposure to cabozantinib has been observed in patients with mild to moderate hepatic
impairment. Reduce the CABOMETYX dose in patients with mild (Child-Pugh score (C-P) A)
or moderate (C-P B) hepatic impairment. CABOMETYX is not recommended for use in patients
with severe hepatic impairment [see Dosage and Administration (2.2), and Clinical
Pharmacology (12.3)].

8.7

Renal Impairment

Dosage adjustment is not required in patients with mild or moderate renal impairment. There is
no experience with CABOMETYX in patients with severe renal impairment [see Clinical
Pharmacology (12.3)].

10

OVERDOSAGE

One case of overdosage was reported in the cabozantinib clinical program; a patient
inadvertently took twice the intended dose (200 mg daily) of another formulation of cabozantinib
product for nine days. The patient suffered Grade 3 memory impairment, Grade 3 mental status
changes, Grade 3 cognitive disturbance, Grade 2 weight loss, and Grade 1 increase in BUN. The
extent of recovery was not documented.

11

DESCRIPTION

CABOMETYX is the (S)-malate salt of cabozantinib, a kinase inhibitor. Cabozantinib (S)-malate
is described chemically as N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4­
fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate. The molecular

11

Reference ID: 3924269

 formula is C28H24FN3O5·C4H6O5 and the molecular weight is 635.6 Daltons as malate salt. The
chemical structure of cabozantinib (S)-malate salt is:
H
N

H
N
O

O

O

MeO

F
O

HO
MeO

OH

N
O

OH

Cabozantinib (S)-malate salt is a white to off-white solid that is practically insoluble in aqueous
media.
CABOMETYX (cabozantinib) tablets are supplied as film-coated tablets containing 20 mg, 40
mg, or 60 mg of cabozantinib, which is equivalent to 25 mg, 51 mg, or 76 mg of cabozantinib
(S)-malate, respectively. CABOMETYX also contains the following inactive ingredients:
microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium,
colloidal silicon dioxide, and magnesium stearate.
The film coating contains hypromellose, titanium dioxide, triacetin, and iron oxide yellow.

12

CLINICAL PHARMACOLOGY

12.1

Mechanism of Action

In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine
kinase activity of MET, VEGFR-1, -2 and -3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB,
FLT-3, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function
and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance,
and maintenance of the tumor microenvironment.

12.2

Pharmacodynamics

The exposure-response or –safety relationship for cabozantinib is unknown.
Cardiac Electrophysiology
The effect of orally administered cabozantinib on QTc interval was evaluated in a randomized,
double-blinded, placebo-controlled study in patients with medullary thyroid cancer administered
a dose of 140 mg. A mean increase in QTcF of 10 - 15 ms was observed at 4 weeks after
initiating cabozantinib. A concentration-QTc relationship could not be definitively established.
Changes in cardiac wave form morphology or new rhythms were not observed. No cabozantinib­
treated patients in this study had a confirmed QTcF > 500 ms nor did any cabozantinib-treated
patients in the RCC study (at a dose of 60 mg).

12

Reference ID: 3924269

 12.3

Pharmacokinetics

Repeat daily dosing of cabozantinib at 140 mg for 19 days resulted in 4- to 5-fold mean
cabozantinib accumulation (based on AUC) compared to a single dose administration; steady
state was achieved by Day 15.
Absorption
Following oral administration of cabozantinib, median time to peak cabozantinib plasma
concentrations (Tmax) ranged from 2 to 3 hours post-dose.
A 19% increase in the Cmax of the tablet formulation (CABOMETYX) compared to the capsule
formulation (COMETRIQ®) was observed following a single 140 mg dose. A less than 10%
difference in the AUC was observed between cabozantinib tablet (CABOMETYX) and capsule
(COMETRIQ) formulations [see Dosage and Administration (2.1)].
Cabozantinib Cmax and AUC values increased by 41% and 57%, respectively, following a highfat meal relative to fasted conditions in healthy subjects administered a single 140 mg oral dose
of an investigational cabozantinib capsule formulation.
Distribution
The oral volume of distribution (Vz/F) of cabozantinib is approximately 319 L. Cabozantinib is
highly protein bound in human plasma (≥ 99.7%).
Elimination
The predicted terminal half-life is approximately 99 hours and the clearance (CL/F) at steadystate is estimated to be 2.2 L/hr.
Metabolism
Cabozantinib is a substrate of CYP3A4 in vitro.
Excretion
Approximately 81% of the total administered radioactivity was recovered within a 48-day
collection period following a single 140 mg dose of an investigational 14C-cabozantinib
formulation in healthy subjects. Approximately 54% was recovered in feces and 27% in urine.
Unchanged cabozantinib accounted for 43% of the total radioactivity in feces and was not
detectable in urine following a 72 hour collection.
Specific Populations
The following patient characteristics did not result in a clinically relevant difference in the
pharmacokinetics of cabozantinib: age (32-86 years), sex, race (Whites and non-Whites), or
mild to moderate renal impairment (eGFR greater than or equal to 30 mL/min/1.73 m2 as
estimated by MDRD (modification of diet in renal disease equation)). The pharmacokinetics of
cabozantinib is unknown in patients with worse than moderate renal impairment (eGFR less than
29 mL/min/1.73m2) as estimated by MDRD equation or renal impairment requiring dialysis.

13

Reference ID: 3924269

 Hepatic Impairment
Cabozantinib exposure (AUC0-inf) increased by 81% and 63%, respectively, in patients with mild
(C-P A) and moderate (C-P B) hepatic impairment. Patients with severe hepatic impairment have
not been studied [see Dosage and Administration (2.2), Use in Specific Populations (8.6)].
Pediatric Population
The pharmacokinetics of cabozantinib has not been studied in the pediatric population [see Use
in Specific Populations (8.4)].
Drug Interactions
CYP3A4 Inhibition on Cabozantinib
Administration of a strong CYP3A4 inhibitor, ketoconazole (400 mg daily for 27 days) to
healthy subjects increased single-dose plasma cabozantinib exposure (AUC0-inf) by 38%.
CYP3A4 Induction on Cabozantinib
Administration of a strong CYP3A4 inducer, rifampin (600 mg daily for 31 days) to healthy
subjects decreased single-dose plasma cabozantinib exposure (AUC0-inf) by 77%.
Cabozantinib on CYP2C8 substrates
No clinically-significant effect on single-dose rosiglitazone (a CYP2C8 substrate) plasma
exposure (Cmax and AUC) was observed when co-administered with cabozantinib at steady-state
plasma concentrations (≥ 100 mg/day daily for a minimum of 21 days) in patients with solid
tumors.
Gastric pH modifying agents on Cabozantinib
No clinically-significant effect on plasma cabozantinib exposure (AUC) was observed following
co-administration of the proton pump inhibitor (PPI) esomeprazole (40 mg daily for 6 days) with
a single dose of 100 mg cabozantinib to healthy volunteers.
In vitro Studies
Metabolic Pathways
Inhibition of CYP3A4 reduced the formation of the oxidative metabolite by > 80%. Inhibition of
CYP2C9 had a minimal effect on cabozantinib metabolite formation (i.e., a <20% reduction).
Inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6 and CYP2E1 had no
effect on cabozantinib metabolite formation.
Although cabozantinib is an inhibitor of CYP2C8 in vitro, a clinical study of this potential
interaction concluded that concurrent use did not result in a clinically relevant effect on CYP2C8
substrate exposure. Given this finding, other less sensitive substrates of pathways affected by
cabozantinib in vitro (i.e., CYP2C9, CYP2C19, and CYP3A4) were not evaluated in a clinical
study because, although a clinically relevant exposure effect cannot be ruled out, it is unlikely.
Cabozantinib does not inhibit CYP1A2 and CYP2D6 isozymes in vitro.
Cabozantinib is an inducer of CYP1A1 mRNA; however, the clinical relevance of this finding is
unknown. Cabozantinib does not induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or
CYP3A4.
14

Reference ID: 3924269

 Drug Transporter Systems
Cabozantinib is an inhibitor, but not a substrate, of P-gp transport activities and has the potential
to increase plasma concentrations of co-administered substrates of P-gp. The clinical relevance
of this finding is unknown.
Cabozantinib is a substrate of MRP2 in vitro and MRP2 inhibitors have the potential to increase
plasma concentrations of cabozantinib. The clinical relevance of this finding is unknown.

13

NONCLINICAL TOXICOLOGY

13.1

Carcinogenesis, Mutagenesis, Impairment of Fertility

Cabozantinib was not carcinogenic in a 26-week carcinogenicity study in rasH2 transgenic mice.
Cabozantinib was not mutagenic in vitro in the bacterial reverse mutation (Ames) assay and was
not clastogenic in both the in vitro cytogenetic assay using human lymphocytes or in the in vivo
mouse micronucleus assay.
Based on nonclinical findings, male and female fertility may be impaired by treatment with
CABOMETYX. In a fertility study in which cabozantinib was administered to male and female
rats at doses of 1, 2.5, and 5 mg/kg/day, male fertility was significantly compromised at doses
equal to or greater than 2.5 mg/kg/day (approximately 13-fold of human AUC at the
recommended dose), with a decrease in sperm counts and reproductive organ weights. In
females, fertility was significantly reduced at doses equal to or greater than 1 mg/kg/day (5-fold
of human AUC at the recommended dose) with a significant decrease in the number of live
embryos and a significant increase in pre- and post-implantation losses.
Observations of effects on reproductive tract tissues in general toxicology studies were
supportive of effects noted in the dedicated fertility study and included hypospermia and absence
of corpora lutea in male and female dogs in a 6-month repeat dose study at plasma exposures
(AUC) approximately 0.5-fold (males) and <0.1-fold (females) of those expected in humans at
the recommended dose. In addition, female rats administered 5 mg/kg/day for 14 days
(approximately 9-fold of human AUC at the recommended dose) exhibited ovarian necrosis.

14

CLINICAL STUDIES

Study 1 was a randomized (1:1), open-label, multicenter study of CABOMETYX versus
everolimus conducted in patients with advanced RCC who had received at least 1 prior anti­
angiogenic therapy. Patients had to have a Karnofsky Performance Score (KPS) ≥ 70%. Patients
were stratified by the number of prior VEGFR tyrosine kinase inhibitors and Memorial Sloan
Kettering Cancer Center (MSKCC) Risk Group.
Patients (N=658) were randomized to receive CABOMETYX (N=330) administered orally at 60
mg daily or everolimus (N=328) administered orally at 10 mg daily. The majority of the patients
were male (75%), with a median age of 62 years. Sixty-nine percent (69%) received only one
prior anti-angiogenic therapy. Patient distribution by MSKCC risk groups was 46% favorable (0
risk factors), 42% intermediate (1 risk factor), and 13% poor (2 or 3 risk factors). Fifty-four
15

Reference ID: 3924269

 percent (54%) of patients had 3 or more organs with metastatic disease, including lung (63%),
lymph nodes (62%), liver (29%), and bone (22%).
The main efficacy outcome measure was progression-free survival (PFS) assessed by a blinded
independent radiology review committee among the first 375 subjects randomized. Other
efficacy endpoints were objective response rate (ORR) and overall survival (OS) in the Intent-toTreat (ITT) population. Tumor assessments were conducted every 8 weeks for the first 12
months, then every 12 weeks thereafter. Patients received treatment until disease progression or
experiencing unacceptable toxicity. Patients on both arms who had disease progression could
continue treatment at the discretion of the investigator.
Statistically significant improvements in PFS, OS, and ORR were demonstrated for
CABOMETYX compared to everolimus (Figures 1 and 2 and Tables 4 and 5).

P r o b a b ilit
o f P r o g r e s s io n - f r eSurvival
e S u r v iv a l
Probability
ofy Progression-free

Figure 1: Progression-Free Survival in Study 1 (First 375 Randomized)
1 .0
0 .9
0 .8
0 .7
0 .6
0 .5
0 .4
0 .3
0 .2

CABOMETYX

0 .1

Everolimus

0 .0
0

Number
No.
at Riskat risk:
CABOMETYX 187
CABOMETYX
Everolimus
188
Everolimus

3

6

9

12

15

18

20
10

6
2

2
0

Months
M o n th s
152
99

92
46

68
29

Table 4: Progression-Free Survival in Study 1 (First 375 Randomized)
Endpoint

Median PFS (95% CI), months

CABOMETYX

Everolimus

N = 187

N = 188

7.4 (5.6, 9.1)

3.8 (3.7, 5.4)

HR (95% CI), p-value1

0.58 (0.45, 0.74), p<0.0001

1

stratified log-rank test with prior VEGFR-targeting TKI therapy (1 vs 2 or more) and MSKCC
prognostic criteria for previously treated patients with RCC (0 vs 1 vs 2 or 3) as stratification factors (per
IVRS data)

16
Reference ID: 3924269

 Figure 2: Overall Survival in Study 1 (ITT)

1 .0

P rProbability
o b a b ilit y o fofOOverall
v e r a ll SSurvival
u r v iv a l

0 .9
0 .8
0 .7
0 .6
0 .5
0 .4
0 .3

CABOMETYX
CABO M ETYX

0 .2

Everolimus
E v e ro lim u s

0 .1
0 .0
0

3

6

9

12

CABOMETYX 330
Everolimus
328

Table 5.

15

18

21

24

27

30

105
82

41
32

6
8

3
1

0
0

Months
M o n th s

Number at risk:
318
307

296
262

264
229

239
202

178
141

Overall Survival and Objective Response Rate in Study 1 (ITT)

Endpoint

Median OS (95% CI), months
HR (95% CI), p-value

CABOMETYX

Everolimus

N = 330

N = 328

21.4 (18.7, NE)

16.5 (14.7, 18.8)

1

Confirmed ORR (partial responses only)
(95% CI)

0.66 (0.53, 0.83), p=0.0003
17% (13%, 22%)

p-value2

3% (2%, 6%)
p<0.0001

1

stratified log-rank test with prior VEGFR-targeting TKI therapy (1 vs 2 or more) and MSKCC
prognostic criteria for previously treated patients with RCC (0 vs 1 vs 2 or 3) as stratification factors (per
IVRS data)
2
chi-squared test

17

Reference ID: 3924269

 16

HOW SUPPLIED/STORAGE AND HANDLING

CABOMETYX tablets are supplied as follows:
60 mg tablets are yellow film-coated, oval shaped with no score, debossed with “XL” on one
side and “60” on the other side of the tablet; available in bottles of 30 tablets:
NDC 42388-023-26
40 mg tablets are yellow film-coated, triangle shaped with no score, debossed with “XL” on one
side and “40” on the other side of the tablet; available in bottles of 30 tablets:
NDC 42388-025-26
20 mg tablets are yellow film-coated, round shaped with no score, debossed with “XL” on one
side and “20” on the other side of the tablet; available in bottles of 30 tablets:
NDC 42388-024-26
Store CABOMETYX at 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to
30°C (59°F to 86°F) [see USP Controlled Room Temperature].

17

PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).
Inform patients of the following:
Hemorrhage: Instruct patients to contact their healthcare provider to seek immediate medical
attention for signs or symptoms of unusual severe bleeding or hemorrhage [see Warnings and
Precautions (5.1)].
Diarrhea: Advise patients to notify their healthcare provider at the first signs of poorly formed or
loose stool or an increased frequency of bowel movements [see Warnings and Precautions
(5.5)].
Palmar-plantar erythrodysesthesia syndrome: Advise patients to contact their healthcare provider
for progressive or intolerable rash [see Warnings and Precautions (5.6)].
Wound healing: Patients should be advised to contact their healthcare provider before any
planned surgeries, including dental surgery [see Dosage and Administration (2.2)].
Drug interactions: Advise patients to inform their healthcare provider of all prescription or
nonprescription medication or herbal products that they are taking.
Weight loss: Advise patients to report significant weight loss.
Embryo-fetal toxicity: Advise females of reproductive potential of the potential risk to a fetus.
Advise females to contact their healthcare provider if they become pregnant, or if pregnancy is
suspected, during treatment with CABOMETYX [see Warnings and Precautions (5.8), Use in
Specific Populations (8.1)].
Females of reproductive potential: Advise patients of reproductive potential to use effective
contraception during treatment with CABOMETYX and for at least four months after the final
dose of CABOMETYX [Use in Specific Populations (8.3)].

18

Reference ID: 3924269

 Lactation: Advise women not to breastfeed during treatment with CABOMETYX and for 4
months following the last dose [Use in Specific Populations (8.2)].
Important Administration Information
•  Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking
CABOMETYX. Instruct patients to not crush CABOMETYX tablets and to take
CABOMETYX tablets with a full glass (at least 8 ounces) of water.
•  Advise patients not to consume grapefruits or grapefruit juice while taking CABOMETYX.
[see Dosage and Administration (2.1)]
Manufactured for Exelixis, Inc. South San Francisco, CA 94080

19

Reference ID: 3924269

 PATIENT INFORMATION
CABOMETYX™ (Ka-boe-met-iks)
cabozantinib
tablets
What is CABOMETYX?
CABOMETYX is a prescription medicine used to treat people with advanced kidney cancer (renal cell carcinoma)
whose cancer has spread or grown after treatment with other cancer medications.
It is not known if CABOMETYX is safe and effective in children.
Before you take CABOMETYX, tell your healthcare provider about all of your medical conditions, including if you:
• have any unusual bleeding
• have high blood pressure
• plan to have any surgery, including dental surgery. You should stop treatment with CABOMETYX at least 28
days before any scheduled surgery.
• have liver problems
• are pregnant, or plan to become pregnant. CABOMETYX can harm your unborn baby. If you are able to become
pregnant, you should use effective birth control during treatment and for 4 months after your final dose of
CABOMETYX. Talk to your healthcare provider about birth control methods that may be right for you. If you
become pregnant or think you are pregnant, tell your healthcare provider right away.
•
are breastfeeding or plan to breastfeed. It is not known if CABOMETYX passes into your breast milk. Do not
breastfeed during treatment and for 4 months after your final dose of CABOMETYX.
Tell your healthcare provider about all the medicines you take, including prescription or over-the-counter
medicines, vitamins, and herbal supplements. CABOMETYX and certain other medicines may affect each other
causing side effects.
How should I take CABOMETYX?
• Take CABOMETYX exactly as your healthcare provider tells you to take it.
• Do not take CABOMETYX with food. Do not eat for at least 2 hours before and at least 1 hour after taking
CABOMETYX.
• Swallow CABOMETYX tablets whole with a full glass (at least 8 ounces) of water.
• Do not crush CABOMETYX tablets.
• If you miss a dose and your next dose is in:
o less than 12 hours, take your next dose at the normal time. Do not make up the missed dose.
o 12 hours or more, take the missed dose as soon as you remember. Take your next dose at the normal time.
What should I avoid while taking CABOMETYX?
Do not drink grapefruit juice, eat grapefruit or supplements that contain grapefruit during treatment with
CABOMETYX.
What are the possible side effects of CABOMETYX?
CABOMETYX may cause serious side effects, including:
• severe bleeding (hemorrhage). Tell your healthcare provider right away if you get any signs of bleeding during
treatment with CABOMETYX, including:
o coughing up blood or blood clots
o red or black (looks like tar) stools
o menstrual bleeding that is heavier than normal
o vomiting blood or if your vomit looks like coffeeo any unusual or heavy bleeding
grounds
• a tear in your stomach or intestinal wall (perforation) or an abnormal connection between 2 parts of your
body (fistula). Tell your healthcare provider right away if you get tenderness or pain in your stomach-area
(abdomen).
• blood clots, stroke, heart attack, and chest pain. Get emergency help right away if you get:
o swelling or pain in your arms or legs
o sudden confusion, trouble speaking or
o shortness of breath
understanding
o feel lightheaded or faint
o sudden trouble seeing in one or both eyes

20
Reference ID: 3924269

 sweating more than usual
o sudden trouble walking
numbness or weakness of your face, arm or leg,
o dizziness, loss of balance or coordination
o a sudden severe headache
especially on one side of your body
• high blood pressure (hypertension). Hypertension is common with CABOMETYX and sometimes can be
severe. Your healthcare provider will check your blood pressure before starting CABOMETYX and during
treatment with CABOMETYX. If needed, your healthcare provider may prescribe medicine to treat your high
blood pressure.
• diarrhea. Diarrhea is common with CABOMETYX and can be severe. If needed, your healthcare provider may
prescribe medicine to treat your diarrhea. Tell your healthcare provider right away, if you have frequent loose,
watery bowel movements.
• a skin problem called hand-foot skin reaction. Hand-foot skin reactions are common and can be severe. Tell
your healthcare provider right away if you have rashes, redness, pain, swelling, or blisters on the palms of your
hands or soles of your feet.
• Reversible Posterior Leukoencephalopathy Syndrome (RPLS). A condition called reversible posterior
leukoencephalopathy syndrome can happen during treatment with CABOMETYX. Tell your healthcare provider
right away if you have headaches, seizures, confusion, changes in vision, or problems thinking.
Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with CABOMETYX
if you have certain side effects.
The most common side effects of CABOMETYX are:
• tiredness
• vomiting
• nausea
• weight loss
• decreased appetite
• constipation
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of CABOMETYX. For more information, ask your healthcare provider or
pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
o
o

How should I store CABOMETYX?
• Store CABOMETYX at room temperature 68°F to 77°F (20°C to 25°C).
Keep CABOMETYX and all medicines out of the reach of children.
General information about CABOMETYX.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use
CABOMETYX for a condition for which it was not prescribed. Do not give CABOMETYX to other people, even if they
have the same symptoms you have. It may harm them.
You can ask your healthcare provider or pharmacist for information about CABOMETYX that is written for health
professionals.
What are the ingredients in CABOMETYX?
Active ingredient: cabozantinib
Inactive ingredients: microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose
sodium, colloidal silicon dioxide, and magnesium stearate. The film coating contains hypromellose, titanium dioxide,
triacetin, and iron oxide yellow.
Manufactured for Exelixis, Inc. South San Francisco, CA 94080
For more information, go to www.cabometyx.com or call 1-855-292-3935.
This Patient Information has been approved by the U.S. Food and Drug Administration.

21

Reference ID: 3924269

Issued: 04/2016